Opinion

Video

UPCOMING SERIES: Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

Trinity Bivalacqua, MD, PhD, announces an upcoming UroView series highlighting key information presented at ASCO 2024 surrounding treatment of high-risk BCG-unresponsive NMIBC.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
doctor holding a pen talking to patient
December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke
“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.
Dr. Chew and Dr. Bhojani highlight their findings on sepsis rates post ureteroscopy
November 2nd 2022

Dr. Chew and Dr. Bhojani highlight their findings on sepsis rates post ureteroscopy

Urology Times staff
Naeem Bhojani, MD, and Ben H. Chew, MD, MSc, FRCSC, discuss the burden of sepsis post-URS to both the healthcare system and patients.
Doctor discusses treatment information with patient
October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke
Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
First European patient treated for urethral stricture with novel drug-coated balloon catheter
February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick
The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.
FDA approves lumasiran as first drug for primary hyperoxaluria type 1
November 24th 2020

FDA approves lumasiran as first drug for primary hyperoxaluria type 1

Jason M. Broderick
The treatment is approved for both adult and pediatric patients.
© 2024 MJH Life Sciences

All rights reserved.